1. Home
  2. NG vs ABCL Comparison

NG vs ABCL Comparison

Compare NG & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novagold Resources Inc.

NG

Novagold Resources Inc.

HOLD

Current Price

$8.29

Market Cap

4.3B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.47

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NG
ABCL
Founded
1984
2012
Country
Canada
Canada
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.5B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
NG
ABCL
Price
$8.29
$11.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$12.22
$8.40
AVG Volume (30 Days)
5.0M
9.1M
Earning Date
04-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$5.08
$2.75
52 Week High
$14.40
$12.58

Technical Indicators

Market Signals
Indicator
NG
ABCL
Relative Strength Index (RSI) 54.05 62.27
Support Level $8.22 $3.39
Resistance Level $8.75 $12.58
Average True Range (ATR) 0.46 0.74
MACD -0.12 -0.15
Stochastic Oscillator 34.76 50.77

Price Performance

Historical Comparison
NG
ABCL

About NG Novagold Resources Inc.

Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: